vTv Therapeutics Inc. Class A Common Stock (VTVT) is a publicly traded Healthcare sector company. As of May 21, 2026, VTVT trades at $36.62 with a market cap of $139.78M and a P/E ratio of 0.00. VTVT moved -0.66% today. Year to date, VTVT is -13.64%; over the trailing twelve months it is +68.51%. Its 52-week range spans $12.62 to $44.00. Analyst consensus is strong buy with an average price target of $53.00. Rallies surfaces VTVT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
vTv Therapeutics Schedules Fireside Chat on Phase 3 Cadisegliatin at ROTH Conference: vTv Therapeutics announced management will present at the 38th Annual ROTH Conference on March 23 with a fireside chat and one-on-one investor meetings, including a live webcast. The company’s Phase 3 cadisegliatin oral therapy for type 1 diabetes, granted FDA Breakthrough Therapy designation, will likely be a key discussion topic.
| Metric | Value |
|---|---|
| Price | $36.62 |
| Market Cap | $139.78M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $44.00 |
| 52-Week Low | $12.62 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $36.84M |
| Net Income | $-729.00K |
| Gross Margin | 0.00% |
6 analysts cover VTVT: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $53.00.